FDA puts commissioner’s priority voucher framework on ice
The US Food and Drug Administration (FDA) appears to have quietly paused the Commissioner’s National Priority Voucher (CNPV) pilot programme,…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund
With an eye on entering the obesity market dominated by Eli Lilly, Pfizer has secured $1.5bn from Blackstone Life Sciences…
-
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Following a series of industry-defining readouts for its personalised cancer vaccine intismeran autogene, Moderna is eyeing a future bigger than…
-
Pentagon drops WuXi AppTec from Chinese military company list
The US Department of Defence (DoD) has removed WuXi AppTec from its list of designated Chinese military companies, easing geopolitical…
-
FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain…
-
Cordavis to stay in CVS Health after bifurcation of $117bn empire
CVS Health will keep biosimilar subsidiary Cordavis under its umbrella, after the company announced plans to split off its pharmacy…
-
Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn
Boehringer Ingelheim has become the latest drugmaker to turn to Sino Biopharmaceutical’s research team, inking a deal worth up to…
-
FDA calls for stronger potency upkeep in CGT manufacturing
Despite moving to loosen certain cell and gene therapy (CGT) quality requirements earlier in the year, the US Food and…
-
Fresenius and WuXi Bio team up in 37-strong biosimilar development deal
Fresenius and WuXi Biologics will work together to develop up to 37 biosimilar candidates targeting a range of therapeutic areas,…
-
Eli Lilly’s tirzepatide outperforms big pharma companies in Q3
Eli Lilly posted another strong quarter fuelled by its obesity franchise medications, with company revenue soaring 39% compared to Q3…